

REMARKS/ARGUMENTS

In the Office Action, the Examiner issued a restriction requirement alleging that the application claims two distinct inventions (Groups I and II).

Group I includes claims 1-17 drawn to a crystal comprising polypeptide of residues 2-384 of SEQ. ID. NO:1, the polypeptide itself, and a method of making crystal, classified in class 435, subclass 183.

Group II includes claims 18-23 drawn to a method of identifying modulator of the polypeptide, classified in class 702, subclass 27.

Pursuant to 37 C.F.R. § 1.142, Applicants hereby elect Group I (claims 1-17) with traverse.

Applicants amend claims directed to Group II (claims 17-23) to depend from claims within elected Group I and thus claims 17-23 should not be subject to restriction.

All now pending claims are directed to elected Group I.


Applicants reserve the right pursuant to 35 U.S.C. § 121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of the present application.

CONCLUSION

Applicants earnestly believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

Respectfully submitted,
TAKEDA SAN DIEGO, INC.

Dated: June 21, 2006

By: 
David J. Weitz
Reg. No. 38,362

Customer No. 32793
Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121
Telephone: (858) 622-8528
Facsimile: (858) 550-0992